Status: Recruiting
Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 20-40Biological sex: FemaleType: InterventionalSponsor: Yan HongliUpdated: Aug 11, 2025Locations: 1
Eligibility criteria
The intention of pregnant women aged >= 20 and < 40, with normal karyotype; [+4]
Unable to follow the treatment observation process required by the trial; [+9]